A5049974669- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Cancer Treatment and Pharmacology
- Cardiac Arrest and Resuscitation
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Breast Cancer Treatment Studies
- Cardiac pacing and defibrillation studies
- Acute Myocardial Infarction Research
- Polyomavirus and related diseases
- Childhood Cancer Survivors' Quality of Life
- Heart Rate Variability and Autonomic Control
- Phonocardiography and Auscultation Techniques
- Pulmonary Hypertension Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Cardiomyopathy and Myosin Studies
- Cancer-related cognitive impairment studies
- Transplantation: Methods and Outcomes
- Aortic Disease and Treatment Approaches
- HER2/EGFR in Cancer Research
- Optimism, Hope, and Well-being
Linköping University
2014-2025
Vrinnevisjukhuset i Norrköping
2023-2024
Sahlgrenska University Hospital
2019
Karolinska Institutet
2018
Karolinska University Hospital
2018
Linköping University Hospital
2004-2016
University of Louisville
2016
Abstract Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, yet genetic cause of up to 50% cases remains unknown. Here, we show that mutations in KLHL24 HCM humans. Using genome-wide linkage analysis and exome sequencing, identified homozygous two consanguineous families with HCM. Of 11 young affected adults identified, 3 died suddenly 1 had a cardiac transplant due heart failure. member Kelch-like protein family, which acts as substrate-specific adaptors...
Mechanical circulatory support technology is continually improving. However, adverse complications do occur with devastating consequences, for example, pump thrombosis that may develop in several parts of the system. The aim this study was to design an experimental clot/thrombosis model register and analyze acoustic signals from left ventricular assist device ( LVAD ) H eart M ate II HMII T horatec C orporation, I nc., P leasanton, CA, USA detect changes sound correlating clots inflow,...
After implantation of a continuous-flow left ventricular assist device (LVAD), atrial pressure (LAP) monitoring allows for the precise management intravascular volume, inotropic therapy, and pump speed. In this case series 4 LVAD recipients, we report first clinical use wireless sensor long-term LAP during support. A microelectromechanical system (Titan, ISS Inc., Ypsilanti, MI) was placed in atrium four patients at time implantation. Titan measured all on intensive care unit three home....
Known risk factors for new-onset atrial fibrillation/flutter (NOAF) include thyrotoxicosis and subclinical hypothyroidism. While prior research has predominantly explored the link between NOAF, presence of hypothyroidism among patients presenting with acute NOAF in emergency department (ED) remains an underexplored area inquiry. This study aimed to assess prevalence undiagnosed diagnosed ED. registry-based cohort was conducted ED at Vrinnevi Hospital Sweden during years 2018, 2020, 2022, a...
Abstract Background Breast cancer (BC) and cardiovascular disease (CVD) are prevalent comorbidities in aging populations. Advances BC treatment have improved survival rates but increased the risk of CVD, particularly among younger patients with BRCA1/2 mutations. gene mutations, patients, impair cardioprotective effects, elevating CVD alongside treatments. This study examined prevalence incidence factors (CVRFs) before after diagnosis mutation carriers (BRCA-BC) those sporadic (Sporadic-BC)....
Background Dose‐dense (DD) adjuvant chemotherapy improves outcomes in early breast cancer (BC). However, there are no phase 3 randomized data to inform on its combination with trastuzumab for patients human epidermal growth factor receptor 2 (HER2)–positive disease. Methods This was a protocol‐predefined secondary analysis of the Pan‐European Tailored Chemotherapy (PANTHER) trial. Women 65 years old or younger node‐positive high‐risk, node‐negative BC were 1:1 either tailored (according...
We report the endovascular stenting of an outflow tract thrombosis in a left ventricular assist device patient with relative contraindications to sternotomy and pump exchange. This highlights importance simultaneous prevention stroke using filter devices common carotid arteries.
Background The administration of anticancer drugs in females with comorbidity increases the risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), which turn contributes to disease (CVD). Furthermore, a pathophysiological connection between and may exist. Objective To assess long-term risks predictors CTR-CVT, including clinical hypertension (HT), coronary artery (CAD), heart failure (HF), atrial fibrillation (AF), as well all-cause mortality women diagnosed early breast (BC)...
Sleep-disordered breathing (SDB) is common in patients with heart failure (HF) and leads to disturbed sleep. The objective of this study was determine the persistent effects long-term nocturnal oxygen treatment severe HF regarding (1) outcomes, such as sleep, SDB, cardiac function, functional capacity; (2) subjective self-assessed sleep difficulties, daytime sleepiness, health-related quality life (HRQOL); (3) relationship between outcomes. In open nonrandomized experimental study, 22...
Objectives. The presence of a mechanical prosthesis has been regarded as an increased risk thromboembolic complications and relative contraindication for left ventricular assist device (LVAD). Five patients in our center had aortic valve at the time implantation were studied regarding complications. Design. operated upon with LVAD (1 HeartMate I™, 4 II™) between 2002 2011 implantation. first patient patch closure valve. In four patients, was place. Anticoagulants included aspirin, warfarin,...
The use of left ventricular assist devices (LVADs) has increased in the last decade. Major complications have been well described, but there is no data on device alarms and actual or threatening malfunction which impair quality life may outcomes. This study describes technical problems related to HVAD® a single center.We retrospectively reviewed malfunctions outcomes 22 patients with followed at Karolinska University Hospital between 2011 2016. Device was defined by INTERMACS as failure one...
Progressive multifocal leukoencephalopathy (PML), caused by reactivation of JC-virus is a relatively rare complication seen in patients with compromised immune system. There are no evidence-based treatment available and prognosis poor. Withdrawal immunosuppressant can result further neurological deterioration for solid organ transplantations, fatal graft rejection. We report 52-year-old women that presented seizures within 1 month after heart transplantation. Initial diagnosis was vascular...
Objectives: The purpose of this study was to assess complications and mortality its predictors, with continuous-flow left ventricular assist devices (CF-LVADs) in the Nordic Countries. Design: This a retrospective, international, multicenter cohort study. Results: Between 1993 2013, 442 surgically implanted long-term mechanical were used among 8 centers countries. Of those, 238 CF-LVADs (HVAD or HeartMate II) patients >18 years complete data. Postoperative survival compared Cox proportion...
Objectives: Left ventricular assist devices (LVAD), used in the setting bridge-to-transplantation and destination therapy, for patients with deteriorating severe heart failure are continuously developing. The second generation, axial flow pumps, have been introduced since some years. Design: Eleven consecutive patients, seven male, due to ischemic cardiomyopathy (n=5), dilated (n=5) cytotoxic ethiology (n=1) were implanted HeartMate-II™. They preoperatively treated inotropic support (n=9),...
Cardiotoxicity is a multifactorial problem, which has emerged with the improvement of cancer therapies and survival. Heart transplantation relatively contraindicated in patients breast cancer, until at least 5 years after complete remission. We present case where young woman who 2001, age 31, was diagnosed cancer. She considered cured, but 4 later she suffered relapse. During her second treatment, 2006, from severe heart failure. received HeartMate II, as long-term bridge to 6 successfully...